


***Remarks***

In the specification, the sequence listing as filed in the Amendment of December 16, 2009, has been replaced with a substitute sequence listing. The sequence listing is the same as that submitted in the December 16, 2009, amendment, which was fully supported in originally filed Figure 5, and is submitted merely in response to the Requirement for Sequence Disclosure Notice dated April 28, 2010. Thus, this amendment adds no new matter, and its entry and consideration are respectfully requested. A copy of the sequence listing in computer readable form (CRF) as required by 37 C.F.R. 1.821(e) is also submitted herewith. In accordance with 37 C.F.R. §§ 1.821-1.825, the computer readable and paper copies of the substitute sequence listing submitted herewith are the same and include no new matter.

Applicants respectfully submit that the application now complies with the requirements for patent applications containing nucleotide sequence and/or amino acid sequence disclosures. Prompt and favorable consideration of this Response is respectfully requested.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Deborah A. Sterling  
Attorney for Applicant  
Registration No. 62,732

Date: May 25, 2010

1100 New York Avenue, N.W.  
Washington, D.C. 20005-3934  
(202) 371-2600  
1113112\_1.DOC